Published in Cancer Res on March 09, 2010
Antimetastatic efficacy of silibinin: molecular mechanisms and therapeutic potential against cancer. Cancer Metastasis Rev (2010) 1.41
Anti-cancer natural products isolated from chinese medicinal herbs. Chin Med (2011) 1.39
Silibinin prevents lung tumorigenesis in wild-type but not in iNOS-/- mice: potential of real-time micro-CT in lung cancer chemoprevention studies. Clin Cancer Res (2010) 1.00
Energy deprivation by silibinin in colorectal cancer cells: a double-edged sword targeting both apoptotic and autophagic machineries. Autophagy (2013) 0.97
Effect of silibinin in human colorectal cancer cells: targeting the activation of NF-κB signaling. Mol Carcinog (2011) 0.96
Inhibition of aldose reductase prevents angiogenesis in vitro and in vivo. Angiogenesis (2011) 0.95
Ethanol-induced mast cell-mediated inflammation leads to increased susceptibility of intestinal tumorigenesis in the APC Δ468 min mouse model of colon cancer. Alcohol Clin Exp Res (2013) 0.94
Targeting tumor microenvironment with silibinin: promise and potential for a translational cancer chemopreventive strategy. Curr Cancer Drug Targets (2013) 0.92
Identifying molecular targets of lifestyle modifications in colon cancer prevention. Front Oncol (2013) 0.87
Silibinin inhibits Wnt/β-catenin signaling by suppressing Wnt co-receptor LRP6 expression in human prostate and breast cancer cells. Cell Signal (2012) 0.87
Silibinin prevents ultraviolet B radiation-induced epidermal damages in JB6 cells and mouse skin in a p53-GADD45α-dependent manner. Carcinogenesis (2011) 0.87
Molecular mechanisms of silibinin-mediated cancer chemoprevention with major emphasis on prostate cancer. AAPS J (2013) 0.86
Phytochemicals and colorectal cancer prevention--myth or reality? Nat Rev Gastroenterol Hepatol (2011) 0.84
Silibinin inhibits ultraviolet B radiation-induced DNA-damage and apoptosis by enhancing interleukin-12 expression in JB6 cells and SKH-1 hairless mouse skin. Mol Carcinog (2013) 0.83
Chemoprevention utility of silibinin and Cdk4 pathway inhibition in Apc(-/+) mice. BMC Cancer (2013) 0.83
Silibinin strongly inhibits the growth kinetics of colon cancer stem cell-enriched spheroids by modulating interleukin 4/6-mediated survival signals. Oncotarget (2014) 0.83
Phytoestrogens/insoluble fibers and colonic estrogen receptor β: randomized, double-blind, placebo-controlled study. World J Gastroenterol (2013) 0.82
Inhibition of intestinal adenoma formation in APC(Min/+) mice by Riccardin D, a natural product derived from liverwort plant Dumortiera hirsuta. PLoS One (2012) 0.82
New Enlightenment of Skin Cancer Chemoprevention through Phytochemicals: In Vitro and In Vivo Studies and the Underlying Mechanisms. Biomed Res Int (2014) 0.81
Silibinin, dexamethasone, and doxycycline as potential therapeutic agents for treating vesicant-inflicted ocular injuries. Toxicol Appl Pharmacol (2012) 0.81
The secondary bile acid, deoxycholate accelerates intestinal adenoma-adenocarcinoma sequence in Apc (min/+) mice through enhancing Wnt signaling. Fam Cancer (2014) 0.80
Null anticarcinogenic effect of silymarin on diethylnitrosamine-induced hepatocarcinogenesis in rats. Exp Ther Med (2013) 0.78
Chemopreventive effects of berberine on intestinal tumor development in Apcmin/+ mice. BMC Gastroenterol (2013) 0.77
Promise and potential of silibinin in colorectal cancer management: what patterns can be seen? Future Oncol (2013) 0.77
Estrogen receptor beta as target for colorectal cancer prevention. Cancer Lett (2015) 0.75
Naringin, a natural dietary compound, prevents intestinal tumorigenesis in Apc (Min/+) mouse model. J Cancer Res Clin Oncol (2015) 0.75
Silibinin and colorectal cancer chemoprevention: a comprehensive review on mechanisms and efficacy. J Biomed Res (2015) 0.75
A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse. Science (1990) 9.90
Proliferating cell nuclear antigen (PCNA): a dancer with many partners. J Cell Sci (2003) 5.26
Minireview: Cyclin D1: normal and abnormal functions. Endocrinology (2004) 5.22
The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis (2009) 5.01
Anti-inflammatory cytokines. Chest (2000) 4.74
Caspases in apoptosis and beyond. Oncogene (2008) 3.47
Point: From animal models to prevention of colon cancer. Systematic review of chemoprevention in min mice and choice of the model system. Cancer Epidemiol Biomarkers Prev (2003) 2.76
The genetics of hereditary colon cancer. Genes Dev (2007) 2.58
Silibinin inhibits established prostate tumor growth, progression, invasion, and metastasis and suppresses tumor angiogenesis and epithelial-mesenchymal transition in transgenic adenocarcinoma of the mouse prostate model mice. Clin Cancer Res (2008) 2.00
beta-Catenin signaling in biological control and cancer. J Cell Biochem (2007) 1.89
VEGF inhibition: insights from preclinical and clinical studies. Cell Tissue Res (2008) 1.76
Colon cancer: preventive agents and the present status of chemoprevention. Expert Opin Pharmacother (2009) 1.64
Life expectancy after colectomy and ileorectal anastomosis for familial adenomatous polyposis. Dis Colon Rectum (1993) 1.64
Cyclooxygenase-2 (cox-2) and the inflammogenesis of cancer. Subcell Biochem (2007) 1.63
Connecting COX-2 and Wnt in cancer. Cancer Cell (2006) 1.59
Silibinin upregulates the expression of cyclin-dependent kinase inhibitors and causes cell cycle arrest and apoptosis in human colon carcinoma HT-29 cells. Oncogene (2003) 1.58
Silymarin: a review of its clinical properties in the management of hepatic disorders. BioDrugs (2001) 1.54
Angioprevention': angiogenesis is a common and key target for cancer chemopreventive agents. FASEB J (2002) 1.51
Wnt breakers in colon cancer. Cancer Cell (2004) 1.46
Chemoprevention of familial adenomatous polyposis by low doses of atorvastatin and celecoxib given individually and in combination to APCMin mice. Cancer Res (2006) 1.43
Cytokines: from gut inflammation to colorectal cancer. Curr Drug Targets (2008) 1.43
Gastroduodenal polyps in patients with familial adenomatous polyposis. Dis Colon Rectum (1992) 1.41
Chemoprevention of familial adenomatous polyposis by natural dietary compounds sulforaphane and dibenzoylmethane alone and in combination in ApcMin/+ mouse. Cancer Res (2007) 1.36
Identification of neovasculature using nestin in colorectal cancer. Int J Oncol (2007) 1.36
Hypoxia-induced angiogenesis during carcinogenesis. J Biochem Mol Biol (2003) 1.32
The role of cyclooxygenase-2 and prostaglandins in colon cancer. Prostaglandins Other Lipid Mediat (2006) 1.29
Stage-specific inhibitory effects and associated mechanisms of silibinin on tumor progression and metastasis in transgenic adenocarcinoma of the mouse prostate model. Cancer Res (2008) 1.29
The role of tissue inhibitors of metalloproteinases in tumorigenesis and metastasis. Crit Rev Clin Lab Sci (2008) 1.28
Silibinin inhibits colorectal cancer growth by inhibiting tumor cell proliferation and angiogenesis. Cancer Res (2008) 1.24
Monocytes and dendritic cells in a hypoxic environment: Spotlights on chemotaxis and migration. Immunobiology (2008) 1.18
Interplay between VHL/HIF1alpha and Wnt/beta-catenin pathways during colorectal tumorigenesis. Oncogene (2006) 1.17
Regulators of angiogenesis and strategies for their therapeutic manipulation. Int J Biochem Cell Biol (2005) 1.16
A rod end deletion in the intermediate filament protein nestin alters its subcellular localization in neuroepithelial cells of transgenic mice. J Cell Sci (1998) 1.10
Mechanisms and preclinical efficacy of silibinin in preventing skin cancer. Eur J Cancer (2005) 1.09
Inhibition of azoxymethane-induced colonic aberrant crypt foci formation by silibinin in male Fisher 344 rats. Cancer Prev Res (Phila) (2008) 1.09
Oral silibinin inhibits in vivo human bladder tumor xenograft growth involving down-regulation of survivin. Clin Cancer Res (2008) 1.08
Advances in the use of milk thistle (Silybum marianum). Integr Cancer Ther (2007) 1.07
Growth inhibition and regression of lung tumors by silibinin: modulation of angiogenesis by macrophage-associated cytokines and nuclear factor-kappaB and signal transducers and activators of transcription 3. Cancer Prev Res (Phila) (2009) 1.02
Tissue distribution of silibinin, the major active constituent of silymarin, in mice and its association with enhancement of phase II enzymes: implications in cancer chemoprevention. Carcinogenesis (1999) 1.01
Silybin and its bioavailable phospholipid complex (IdB 1016) potentiate in vitro and in vivo the activity of cisplatin. Life Sci (2002) 0.94
Pro-angiogenic cytokines and their role in tumor angiogenesis. Cancer Metastasis Rev (2006) 0.92
Detecting mutations in the APC gene in familial adenomatous polyposis (FAP). Curr Protoc Hum Genet (2006) 0.91
Silymarin and epithelial cancer chemoprevention: how close we are to bedside? Toxicol Appl Pharmacol (2006) 0.91
Biomarkers of WNT signaling. Cancer Biomark (2007) 0.91
The development of duodenal microadenomas in FAP patients: the human correlate of the Min mouse. J Pathol (2008) 0.90
Nitric oxide synthase expression in human bladder cancer and its relation to angiogenesis. Urol Res (2003) 0.86
Assessment of biomarkers in paired primary and recurrent colorectal adenocarcinomas. Int J Radiat Oncol Biol Phys (1999) 0.84
Angiogenesis and hypoxic factors in colorectal cancer. Pathol Res Pract (2008) 0.83
Correlation of endothelial nitric oxide synthase and vascular endothelial growth factor expression with malignancy in patients with astrocytic tumors. J BUON (2007) 0.81
Silibinin strongly synergizes human prostate carcinoma DU145 cells to doxorubicin-induced growth Inhibition, G2-M arrest, and apoptosis. Clin Cancer Res (2002) 2.55
Silibinin inhibits established prostate tumor growth, progression, invasion, and metastasis and suppresses tumor angiogenesis and epithelial-mesenchymal transition in transgenic adenocarcinoma of the mouse prostate model mice. Clin Cancer Res (2008) 2.00
Anticancer potential of silymarin: from bench to bed side. Anticancer Res (2007) 1.91
Multitargeted therapy of cancer by silymarin. Cancer Lett (2008) 1.66
A phase I and pharmacokinetic study of silybin-phytosome in prostate cancer patients. Invest New Drugs (2006) 1.63
Gram-scale purification of flavonolignan diastereoisomers from Silybum marianum (Milk Thistle) extract in support of preclinical in vivo studies for prostate cancer chemoprevention. Planta Med (2007) 1.61
Milk thistle and prostate cancer: differential effects of pure flavonolignans from Silybum marianum on antiproliferative end points in human prostate carcinoma cells. Cancer Res (2005) 1.61
Silibinin upregulates the expression of cyclin-dependent kinase inhibitors and causes cell cycle arrest and apoptosis in human colon carcinoma HT-29 cells. Oncogene (2003) 1.58
Effect of silibinin on the growth and progression of primary lung tumors in mice. J Natl Cancer Inst (2006) 1.55
Epidermal growth factor receptor mediates silibinin-induced cytotoxicity in a rat glioma cell line. Cancer Biol Ther (2003) 1.46
Oral grape seed extract inhibits prostate tumor growth and progression in TRAMP mice. Cancer Res (2007) 1.46
Grape seed extract inhibits in vitro and in vivo growth of human colorectal carcinoma cells. Clin Cancer Res (2006) 1.46
Silibinin inhibits inflammatory and angiogenic attributes in photocarcinogenesis in SKH-1 hairless mice. Cancer Res (2007) 1.45
Anti-tumor activity of oxypeucedanin from Ostericum koreanum against human prostate carcinoma DU145 cells. Acta Oncol (2009) 1.43
Antimetastatic efficacy of silibinin: molecular mechanisms and therapeutic potential against cancer. Cancer Metastasis Rev (2010) 1.41
p21 and p27 induction by silibinin is essential for its cell cycle arrest effect in prostate carcinoma cells. Mol Cancer Ther (2007) 1.40
Resveratrol causes Cdc2-tyr15 phosphorylation via ATM/ATR-Chk1/2-Cdc25C pathway as a central mechanism for S phase arrest in human ovarian carcinoma Ovcar-3 cells. Carcinogenesis (2005) 1.37
Dietary feeding of silibinin inhibits advance human prostate carcinoma growth in athymic nude mice and increases plasma insulin-like growth factor-binding protein-3 levels. Cancer Res (2002) 1.36
Mechanisms of action of novel agents for prostate cancer chemoprevention. Endocr Relat Cancer (2006) 1.36
Grape seed extract inhibits advanced human prostate tumor growth and angiogenesis and upregulates insulin-like growth factor binding protein-3. Int J Cancer (2004) 1.35
Natural products and colon cancer: current status and future prospects. Drug Dev Res (2008) 1.34
Anticancer and cancer chemopreventive potential of grape seed extract and other grape-based products. J Nutr (2009) 1.33
Stage-specific inhibitory effects and associated mechanisms of silibinin on tumor progression and metastasis in transgenic adenocarcinoma of the mouse prostate model. Cancer Res (2008) 1.29
Silibinin suppresses in vivo growth of human prostate carcinoma PC-3 tumor xenograft. Carcinogenesis (2007) 1.29
Prostate cancer chemoprevention by silibinin: bench to bedside. Mol Carcinog (2006) 1.27
Phytochemicals as cell cycle modulators--a less toxic approach in halting human cancers. Cell Cycle (2002) 1.27
Oral silibinin inhibits lung tumor growth in athymic nude mice and forms a novel chemocombination with doxorubicin targeting nuclear factor kappaB-mediated inducible chemoresistance. Clin Cancer Res (2004) 1.25
Silibinin inhibits colorectal cancer growth by inhibiting tumor cell proliferation and angiogenesis. Cancer Res (2008) 1.24
Dietary feeding of silibinin inhibits prostate tumor growth and progression in transgenic adenocarcinoma of the mouse prostate model. Cancer Res (2007) 1.22
Inflammatory biomarkers of sulfur mustard analog 2-chloroethyl ethyl sulfide-induced skin injury in SKH-1 hairless mice. Toxicol Sci (2008) 1.22
Inositol hexaphosphate inhibits growth, and induces G1 arrest and apoptotic death of prostate carcinoma DU145 cells: modulation of CDKI-CDK-cyclin and pRb-related protein-E2F complexes. Carcinogenesis (2003) 1.21
Genetically engineered bacteria: an emerging tool for environmental remediation and future research perspectives. Gene (2011) 1.19
A study of high-dose oral silybin-phytosome followed by prostatectomy in patients with localized prostate cancer. Prostate (2010) 1.18
Suppression of advanced human prostate tumor growth in athymic mice by silibinin feeding is associated with reduced cell proliferation, increased apoptosis, and inhibition of angiogenesis. Cancer Epidemiol Biomarkers Prev (2003) 1.18
Chemopreventive effects of oral gallic acid feeding on tumor growth and progression in TRAMP mice. Mol Cancer Ther (2008) 1.16
Tumor progression stage and anatomical site regulate tumor-associated macrophage and bone marrow-derived monocyte polarization. Am J Pathol (2010) 1.16
Silymarin inhibits growth and causes regression of established skin tumors in SENCAR mice via modulation of mitogen-activated protein kinases and induction of apoptosis. Carcinogenesis (2002) 1.16
Grape seed extract induces apoptotic death of human prostate carcinoma DU145 cells via caspases activation accompanied by dissipation of mitochondrial membrane potential and cytochrome c release. Carcinogenesis (2002) 1.15
Silibinin protects against photocarcinogenesis via modulation of cell cycle regulators, mitogen-activated protein kinases, and Akt signaling. Cancer Res (2004) 1.15
Gallic acid causes inactivating phosphorylation of cdc25A/cdc25C-cdc2 via ATM-Chk2 activation, leading to cell cycle arrest, and induces apoptosis in human prostate carcinoma DU145 cells. Mol Cancer Ther (2006) 1.15
Synergistic anti-cancer effects of silibinin with conventional cytotoxic agents doxorubicin, cisplatin and carboplatin against human breast carcinoma MCF-7 and MDA-MB468 cells. Oncol Rep (2004) 1.15
Sulfur mustard analog induces oxidative stress and activates signaling cascades in the skin of SKH-1 hairless mice. Free Radic Biol Med (2009) 1.15
Tumor angiogenesis--a potential target in cancer chemoprevention. Food Chem Toxicol (2007) 1.14
Isosilybin B and isosilybin A inhibit growth, induce G1 arrest and cause apoptosis in human prostate cancer LNCaP and 22Rv1 cells. Carcinogenesis (2007) 1.14
Silibinin suppresses growth and induces apoptotic death of human colorectal carcinoma LoVo cells in culture and tumor xenograft. Mol Cancer Ther (2009) 1.13
Fractionation of grape seed extract and identification of gallic acid as one of the major active constituents causing growth inhibition and apoptotic death of DU145 human prostate carcinoma cells. Carcinogenesis (2006) 1.13
Identifying the differential effects of silymarin constituents on cell growth and cell cycle regulatory molecules in human prostate cancer cells. Int J Cancer (2008) 1.12
Gallic acid, an active constituent of grape seed extract, exhibits anti-proliferative, pro-apoptotic and anti-tumorigenic effects against prostate carcinoma xenograft growth in nude mice. Pharm Res (2009) 1.12
In vivo suppression of hormone-refractory prostate cancer growth by inositol hexaphosphate: induction of insulin-like growth factor binding protein-3 and inhibition of vascular endothelial growth factor. Clin Cancer Res (2004) 1.12
Silibinin suppresses growth of human colorectal carcinoma SW480 cells in culture and xenograft through down-regulation of beta-catenin-dependent signaling. Neoplasia (2010) 1.12
Metformin suppresses growth of human head and neck squamous cell carcinoma via global inhibition of protein translation. Cell Cycle (2012) 1.11
Antiproliferative and apoptotic effects of silibinin in rat prostate cancer cells. Prostate (2002) 1.10
Mechanisms and preclinical efficacy of silibinin in preventing skin cancer. Eur J Cancer (2005) 1.09
Inhibition of azoxymethane-induced colonic aberrant crypt foci formation by silibinin in male Fisher 344 rats. Cancer Prev Res (Phila) (2008) 1.09
Chemopreventive efficacy of silymarin in skin and prostate cancer. Integr Cancer Ther (2007) 1.08
Oral silibinin inhibits in vivo human bladder tumor xenograft growth involving down-regulation of survivin. Clin Cancer Res (2008) 1.08
Isosilibinin inhibits advanced human prostate cancer growth in athymic nude mice: comparison with silymarin and silibinin. Int J Cancer (2008) 1.07
Silibinin inhibits constitutive activation of Stat3, and causes caspase activation and apoptotic death of human prostate carcinoma DU145 cells. Carcinogenesis (2007) 1.07
A novel anticancer agent, decursin, induces G1 arrest and apoptosis in human prostate carcinoma cells. Cancer Res (2005) 1.07
Grape seed extract induces cell cycle arrest and apoptosis in human colon carcinoma cells. Nutr Cancer (2008) 1.05
Synergistic anti-cancer effects of grape seed extract and conventional cytotoxic agent doxorubicin against human breast carcinoma cells. Breast Cancer Res Treat (2004) 1.05
Silibinin inhibits ultraviolet B radiation-induced mitogenic and survival signaling, and associated biological responses in SKH-1 mouse skin. Carcinogenesis (2005) 1.05
p21/Cip1 and p27/Kip1 Are essential molecular targets of inositol hexaphosphate for its antitumor efficacy against prostate cancer. Cancer Res (2009) 1.04
Silibinin causes cell cycle arrest and apoptosis in human bladder transitional cell carcinoma cells by regulating CDKI-CDK-cyclin cascade, and caspase 3 and PARP cleavages. Carcinogenesis (2004) 1.04
Dietary feeding of grape seed extract prevents intestinal tumorigenesis in APCmin/+ mice. Neoplasia (2010) 1.04
Silibinin prevents ultraviolet radiation-caused skin damages in SKH-1 hairless mice via a decrease in thymine dimer positive cells and an up-regulation of p53-p21/Cip1 in epidermis. Carcinogenesis (2004) 1.03
Grape seed extract induces anoikis and caspase-mediated apoptosis in human prostate carcinoma LNCaP cells: possible role of ataxia telangiectasia mutated-p53 activation. Mol Cancer Ther (2006) 1.03
Effects of phytochemicals on ionization radiation-mediated carcinogenesis and cancer therapy. Mutat Res (2011) 1.02
Chemopreventive effects of silymarin and silibinin on N-butyl-N-(4-hydroxybutyl) nitrosamine induced urinary bladder carcinogenesis in male ICR mice. Mol Cancer Ther (2007) 1.02